Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Sea Limited
SE
|
$874M |
| 2 |
Coupang
CPNG
|
$809M |
| 3 |
Roblox
RBLX
|
$363M |
| 4 |
Analog Devices
ADI
|
$309M |
| 5 |
Adobe
ADBE
|
$255M |
Top Sells
| 1 |
Tesla
TSLA
|
$1.06B |
| 2 |
Petrobras
PBR
|
$460M |
| 3 |
Alibaba
BABA
|
$450M |
| 4 |
Zillow
Z
|
$381M |
| 5 |
NVIDIA
NVDA
|
$379M |
Sector Composition
| 1 | Consumer Discretionary | 28.1% |
| 2 | Healthcare | 23.85% |
| 3 | Technology | 19.62% |
| 4 | Communication Services | 11.36% |
| 5 | Financials | 5.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Cisco
CSCO
$269B
| $45.4M | 0.03% |
814,703
+48,017
| +6% | +$2.68M |
|
177
Golub Capital BDC
GBDC
$3.94B
| $45.3M | 0.03% |
2,978,235
-466,600
| -14% | -$7.1M |
|
178
JFrog
FROG
$5.65B
| $44.5M | 0.03% |
1,652,682
-33,386
| -2% | -$900K |
|
179
Q2 Holdings
QTWO
$4.82B
| $44.2M | 0.03% |
716,888
-15,274
| -2% | -$942K |
|
180
Royalty Pharma
RPRX
$16B
| $43.9M | 0.03% |
+1,127,031
| New | +$43.9M |
|
181
McDonald's
MCD
$226B
| $43.8M | 0.03% |
176,999
+6,450
| +4% | +$1.59M |
|
182
Schrodinger
SDGR
$1.4B
| $43.1M | 0.03% |
1,262,851
+1,262,609
| +521,739% | +$43.1M |
|
183
Medtronic
MDT
$119B
| $41M | 0.03% |
369,380
+22,292
| +6% | +$2.47M |
|
184
IPG Photonics
IPGP
$3.48B
| $40.8M | 0.03% |
372,129
-10,500
| -3% | -$1.15M |
|
185
Cullen/Frost Bankers
CFR
$8.38B
| $40.5M | 0.03% |
292,820
+19,936
| +7% | +$2.76M |
|
186
Tandem Diabetes Care
TNDM
$837M
| $38.8M | 0.03% |
333,801
-23,151
| -6% | -$2.69M |
|
187
T Rowe Price
TROW
$24.5B
| $35.4M | 0.02% |
234,464
+14,288
| +6% | +$2.16M |
|
188
Futu Holdings
FUTU
$26.3B
| $34.5M | 0.02% |
1,060,019
+31,965
| +3% | +$1.04M |
|
|
EVBG
189
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $34M | 0.02% |
778,984
-18,443
| -2% | -$805K |
|
190
Starbucks
SBUX
$98.9B
| $32.6M | 0.02% |
358,360
+21,341
| +6% | +$1.94M |
|
|
ADAP
191
Adaptimmune Therapeutics
ADAP
$13.5M
| $31.7M | 0.02% |
15,380,538
+1,624,186
| +12% | +$3.35M |
|
192
LivePerson
LPSN
$86.3M
| $30.6M | 0.02% |
1,252,018
-36,073
| -3% | -$881K |
|
193
Dolby
DLB
$6.98B
| $29.8M | 0.02% |
381,212
+25,536
| +7% | +$2M |
|
194
Veeco
VECO
$1.44B
| $28M | 0.02% |
1,031,483
-350,045
| -25% | -$9.52M |
|
195
Clover Health Investments
CLOV
$1.38B
| $27.6M | 0.02% |
7,787,680
| – | – |
|
|
RUBY
196
DELISTED
Rubius Therapeutics, Inc
RUBY
| $27M | 0.02% |
4,907,471
-23,388
| -0.5% | -$129K |
|
197
Clear Secure
YOU
$3.41B
| $26.9M | 0.02% |
1,000,000
| – | – |
|
198
Sixth Street Specialty
TSLX
$2.33B
| $26M | 0.02% |
1,114,700
-975,100
| -47% | -$22.7M |
|
|
CELL
199
DELISTED
PhenomeX Inc. Common Stock
CELL
| $25.2M | 0.02% |
3,539,906
+211,420
| +6% | +$1.5M |
|
200
dLocal
DLO
$3.77B
| $25M | 0.02% |
800,142
| – | – |
|